Decentralized Manufacturing for Cell and Gene Therapies

This document is a guide that outlines the challenges and solutions associated with the decentralization of cell and gene therapy manufacturing. It emphasizes the need for a systematic approach to establish fully functional and licensed point of care facilities that can deliver cell-based therapies locally. The guide details the complexities involved in cell and gene therapy manufacturing, including regulatory hurdles, GxP requirements, and the logistics of raw materials. It discusses the importance of defining success in terms of creating compliant facilities and the steps necessary to build and operate these facilities effectively. Additionally, the guide highlights the need for extensive education, training, and process validation to ensure the safety and efficacy of treatments. ProPharma’s role in facilitating these processes through regulatory planning, facility design, and quality assurance is also presented, aiming to improve patient access to these innovative therapies.